US Patent Issued to Syndax Pharmaceuticals on Feb. 17 for "CSF-1R antibodies for the treatment of chronic graft versus host disease" (Pennsylvania, Massachusetts, New York Inventors)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,552,869, issued on Feb. 17, was assigned to Syndax Pharmaceuticals Inc. (New York).

"CSF-1R antibodies for the treatment of chronic graft versus host disease" was invented by Peter Ordentlich (Lexington, Mass.), Michael Meyers (Hastings-on-Hudson, N.Y.) and Briggs W. Morrison (Newtown, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to methods of treating sclerotic conditions and more specifically to methods of treating chronic graft versus host disease with specific dosages of an anti-CSF-1R antibody, specifically axatilimab."

The patent was filed on Dec. 9, 2020, under Application No. 17/783,552.

*For further informa...